Researchers Supercharge Immune Cells to Target Prostate Cancer

Overcoming T Cell Tolerance to Tumor Self-Antigens through Catch-Bond Engineering

Investigators engineered a new class of supercharged T cells that are stronger, longer-lasting, and more precise at killing prostate cancer cells by fine-tuning how they physically interact with tumor cells. [Science] AbstractPress ReleaseGraphical Abstract

Modifying T Cell Receptor Improves Targeted Cancer Therapy

Much of the challenge in developing cancer therapies is determining methods to improve the effectiveness of the immune system’s ability to identify and kill cancer cells. While therapies like CAR T and check point inhibitors help in cancer treatment, they have their limitations. A cross-country research group from the University of California, Los Angeles (UCLA), Stanford School of Medicine, University of Utah, and Columbia University have engin…

Scientists "Turbocharge" Immune Cells to Attack Prostate Cancer

BYLINE: Denise Heady Newswise — UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, have engineered a new class of supercharged T cells that are stronger, longer-lasting, and more precise at killing prostate cancer cells by fine-tuning how they physically interact with tumor cells. Instead of simply making T cell receptors bind more tightly to cancer, the team, collaborati…

Researchers Supercharge Immune Cells to Target Prostate Cancer

Researchers from UCLA and Stanford Medicine, in collaboration with teams from the University of Utah and Columbia University, have unveiled a groundbreaking advancement in cancer immunotherapy: a novel class of supercharged T cells engineered to exhibit enhanced strength, longevity, and precision in targeting prostate cancer cells. This innovation stems from a sophisticated fine-tuning of the […]